美股市场个股详情

ARWR Arrowhead Pharmaceuticals

添加自选

24.520
+0.390+1.62%

交易中 05/03 11:01 (美东)

30.38亿总市值-8851市盈率TTM

Arrowhead Pharmaceuticals股票讨论区

登录发表评论

stockhub

04/08 00:23

Hope price action is consistent with result

Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
$Arrowhead Pharmaceuticals(ARWR.US)$

投资圆桌会

Tonyco

04/07 11:01

$Arrowhead Pharmaceuticals(ARWR.US)$
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?

Moomoo AI

03/08 19:54

The company's poor performance and the CEO's high pay, despite falling earnings and shareholder value, may upset shareholders. The upcoming AGM on March 14th is a chance for shareholders to hold the board and management accountable.

We Think Shareholders May Want To Consider A Review Of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

zulia3003

03/08 01:34

$Arrowhead Pharmaceuticals(ARWR.US)$ why drop today?

AuthPresidentColor8c

03/02 00:33

$Arrowhead Pharmaceuticals(ARWR.US)$ such a odd spot here

Yemaozi

02/29 02:30

$Arrowhead Pharmaceuticals(ARWR.US)$log Chatter表示：“关注情况的人听说有人猜测Arrowhead Pharmicals最近拒绝了每股45美元左右的指示性方针。“; 股价飙升

ApextradezCOM

02/26 05:54

PH.2 Results + ER Win =🚀

$塞德斯医疗(CLDX.US)$
$Arrowhead Pharmaceuticals(ARWR.US)$ - Alpha Early Alert 🚨 H&S 📈🎯🚀🥇 (45.00) is on the Table 🫵🏻💪🏻🥇 Find the Apex and win!

Moomoo AI

01/04 20:44

The company's P/S ratio is high in contrast to its lower projected growth, a divergence that could bring risk to shareholders and potential investors. The current P/S ratio might not sustain due to predicted future revenues.

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 36% But Its Business Is Yet to Catch Up

Moomoo AI

2023/12/14 23:54

High level of risk for Arrowhead Pharmaceuticals with negative EBIT and a dip in free cash flow. The company burnt US$331m, reported a US$205m loss raising capital raising flags. Investors monitor balance sheet and warning signs needed.

Health Check: How Prudently Does Arrowhead Pharmaceuticals (NASDAQ:ARWR) Use Debt?

Moomoo AI

2023/11/23 18:30

Javier San Martin's insider sale at current price level is not a major concern, nor a positive sign. The lack of insider buying over the past year and mediocre level of insider ownership warrant caution in purchasing its stock.

Arrowhead Pharmaceuticals Chief Medical Officer Javier San Martin Sells 36% Of Holding

暂无评论

分析

分析师评级

暂无数据

目标价预测

暂无数据

热议

美股

综合热度